Skip to main content

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low137.10
Day High139.85
Open:138.72
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDFRefinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDFStockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Premium PDFValueEngine

Press & news

Latest News

More Stories
2 Dividend Kings on Sale That Are Yielding More Than 4%
Motley Fool - Thu May 25, 8:37AM CDT
Motley Fool
Thu May 25, 8:37AM CDT
Before you rush out to buy these stocks, you should consider the risks that come with them.
2 Top Dividend Kings to Buy for the Long Haul
Motley Fool - Thu May 25, 8:00AM CDT
Motley Fool
Thu May 25, 8:00AM CDT
Dividend stocks are an easy way to earn passive income.
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
PR Newswire - Thu May 25, 7:45AM CDT
PR Newswire
Thu May 25, 7:45AM CDT
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials –...

Latest Articles

Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
How this money manager of women-led active ETFs is playing an economic ‘soft landing’
What to watch out for when investing in spin-offs
number cruncher
Strategy focuses on U.S. large caps with upward price momentum
Market movers: Stocks that saw action on Thursday - and why
Why this portfolio manager thinks dividend-paying companies will be more important in times of inflation
Six bargain dividend stocks for investors to play a market rebound
Teva lied to evade accountability for role in New York’s opioid crisis, state attorney-general says
number cruncher
Two dozen ‘steady eddy’ U.S. dividend stocks for the summer doldrums
Buffett’s Berkshire buys Citigroup and several other stocks, slashes Verizon
Johnson & Johnson agrees to pay $99-million to settle opioid-related claims by state of West Virginia
Florida accuses Walgreens of feeding opioid crisis as civil trial against pharmacy chain begins

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.